Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Lesions of Basal Ganglia Due to Disulfiram Neurotoxicity
JNNP 55:925-929, Laplane,D.,et al, 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Individual Dopaminergic Neurons Show Raised Iron Levels in Parkinson Disease
Neurol 68:1820-1825, Oakley,A.E.,et al, 2007
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
MR Imaging Findings After Stereotactic Radiosurgery Using the Gamma Knife
AJR 176:1589-1595, Friedman,D.P.,et al, 2001
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Prevalence and Clinical Correlates of Psychotic Symptoms in parkinson Disease
Arch Neurol 56:595-601, Aarsland,D.,et al, 1999
Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999
Stereotactic Radiosurgical Pallidotomy and Thalamotomy with the Gamma Knife:MR Imaging Findings with Clinical Correlation-Preliminary Experience
Radiology 212:143-150, Friedman,D.P.,et al, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
The Risk of Parkinson's Disease with Exposure to Pesticides, Farming, Well Water, and Rural Living
Neurol 50:1346-1350, Gorell,J.M.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Occupational Exposures to Metals as Risk Factors for Parkinson's Disease
Neurol 48:650-658, Gorell,J.M.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Manganese Toxicity in Children Receiving Long-Term Parental Nutrition
Lancet 347:1218-1221, Fell,J.M.E.,et al, 1996
Diffuse Lewy Body Disease:Clinical Features in Nine Cases without Coexistent Alzheimer's Disease
JNNP 60:531-538, Hely,M.A.,et al, 1996